AstraZeneca sells anaesthetic rights to AspenStaff Writer | September 1, 2016
AstraZeneca has completed its commercialisation agreement with Aspen Global Incorporated, for rights to its global anaesthetics portfolio outside the U.S.
Pharma AstraZeneca sold seven established medicines
"As AstraZeneca will retain a significant ongoing interest in the portfolio, the upfront payment - to be recognised in the third quarter of 2016 - along with all future milestone and royalty payments, will be reported as externalisation revenue in the company's financial statements," AstraZeneva's board said in a statement.
The externalisation came after AstraZeneca was found paying Chinese medical experts large "speaking fees" to share their knowledge at events which never took place. ■